News
Media Contact
Glen Allen, VA (May 7, 2026) — Kaléo, a global leader in drug-device technology and auto-injector innovation, has launched a new Medical Affairs website. This new digital destination is designed to provide healthcare professionals (HCPs) with disease education, clinical data, emerging medical and scientific insights, and information they can share with patients and caregivers.The site is designed to support informed decision-making in patient care, with a particular focus on anaphylaxis—especially in pediatrics, including infants and toddlers.
The platform serves as a centralized hub for anaphylaxis clinical data, peer-reviewed publications, congress-presented research, and real-world evidence related to Kaléo’s therapies and drug-device combination technologies, including its Aerio™ auto-injector platform. By making complex scientific information more accessible, Kaléo Medical Affairs aims to bridge the gap between clinical research and real-world application in patient care.
An important goal of the Kaléo Medical Affairs website is to translate complex clinical insights into practical, actionable information in support of HCPs efforts to assist their patients’ and caregivers’ preparedness and outcomes in allergic emergencies.
Key elements of the site include:
The launch of Kaléo Medical Affairs reflects the company’s continued commitment to scientific exchange, and advancing HCP education. Explore the new site and access the latest medical information at www.kaleomedicalaffairs.com.
###
CC-US–0208
